

Press release

May 26, 2021

Gunilla Lundmark new board member of CombiGene

At CombiGene's Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions in the life science industry. Gunilla's successful entrepreneurship was manifested in 2014 in the "2014 BioTech Builder Prize". Gunilla is the CEO of Uppsala University Invest AB since 2018 and has previously held a number of leading positions at companies such as Pharmanest AB and Q-Med AB.

"Gunilla's long experience of the life science industry and her stated entrepreneurial skills will mean a lot to the continued development of CombiGene," CombiGene Chairman Bert Junno comments.

"I am very much looking forward to being part of CombiGene's Board of Directors. I'm impressed with the company's work so far. CombiGene has a very exciting and promising time ahead of it, not least in the epilepsy project that is approaching the first study in humans," says Gunilla Lundmark.

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

For more information:

CombiGene AB (publ)
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the Board
Tel: +46(0) 70 7 77 22 09
bert.junno@combigene.com

Please read INGENEIOUS, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. INGENEIOUS and press releases are available at www.combigene.com